% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wennmann:141407,
      author       = {M. Wennmann and L. Kintzelé and M. Piraud and B. H. Menze
                      and T. Hielscher$^*$ and J. Hofmanninger and B. Wagner and
                      H.-U. Kauczor and M. Merz and J. Hillengass and G. Langs and
                      M.-A. Weber},
      title        = {{V}olumetry based biomarker speed of growth: {Q}uantifying
                      the change of total tumor volume in whole-body magnetic
                      resonance imaging over time improves risk stratification of
                      smoldering multiple myeloma patients.},
      journal      = {OncoTarget},
      volume       = {9},
      number       = {38},
      issn         = {1949-2553},
      address      = {[S.l.]},
      publisher    = {Impact Journals LLC},
      reportid     = {DKFZ-2018-01913},
      pages        = {25254-25264},
      year         = {2018},
      abstract     = {The purpose of this study was to improve risk
                      stratification of smoldering multiple myeloma patients,
                      introducing new 3D-volumetry based imaging biomarkers
                      derived from whole-body MRI. Two-hundred twenty whole-body
                      MRIs from 63 patients with smoldering multiple myeloma were
                      retrospectively analyzed and all focal lesions >5mm were
                      manually segmented for volume quantification. The imaging
                      biomarkers total tumor volume, speed of growth (development
                      of the total tumor volume over time), number of focal
                      lesions, development of the number of focal lesions over
                      time and the recent imaging biomarker '>1 focal lesion' of
                      the International Myeloma Working Group were compared,
                      taking 2-year progression rate, sensitivity and false
                      positive rate into account. Speed of growth, using a cutoff
                      of 114mm3/month, was able to isolate a high-risk group with
                      a 2-year progression rate of $82.5\%.$ Additionally, it
                      showed by far the highest sensitivity in this study and in
                      comparison to other biomarkers in the literature, detecting
                      $63.2\%$ of patients who progress within 2 years.
                      Furthermore, its false positive rate $(8.7\%)$ was much
                      lower compared to the recent imaging biomarker '>1 focal
                      lesion' of the International Myeloma Working Group.
                      Therefore, speed of growth is the preferable imaging
                      biomarker for risk stratification of smoldering multiple
                      myeloma patients.},
      cin          = {C060},
      ddc          = {610},
      cid          = {I:(DE-He78)C060-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:29861868},
      pmc          = {pmc:PMC5982766},
      doi          = {10.18632/oncotarget.25402},
      url          = {https://inrepo02.dkfz.de/record/141407},
}